Abstract
Rituximab may be effective in the treatment of ocular inflammatory disease. Dosing is less frequent than many medications currently available. Four cases are reported, each of which appeared to have responded well to treatment with rituximab, although patient 2 was able to remain on a low dose of prednisone for only 2 months. The ongoing pilot study will hopefully provide additional insight into the benefit of rituximab for treatment of scleritis and idiopathic orbital inflammatory disease.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 546-548 |
| Number of pages | 3 |
| Journal | British Journal of Ophthalmology |
| Volume | 93 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2009 |
ASJC Scopus subject areas
- Ophthalmology
- Sensory Systems
- Cellular and Molecular Neuroscience